Arimoclomol: First Approval
Author:
- 24 December 2024
- journal article
- research article
- Published by Springer Nature in Drugs
- Vol. 85 (1) , 111-116
Abstract
Arimoclomol (MIPLYFFA™), an oral small molecule that crosses the blood brain barrier and is thought to upregulate CLEAR (Coordinated Lysosomal Expression and Regulation) network genes and improve lysosomal function, is being developed by Zevra Therapeutics Inc., for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC). In September 2024, arimoclomol was approved for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients 2 years of age and older in the USA. This article summarizes the milestones in the development of arimoclomol leading to this first approval for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients aged ≥ 2 years.Keywords
This publication has 11 references indexed in Scilit:
- Extracellular Self-DNA Effects on Yeast Cell Cycle and Transcriptome during Batch GrowthBiomolecules, 2024
- Alterations in Proteostasis Mechanisms in Niemann–Pick Type C DiseaseInternational Journal of Molecular Sciences, 2024
- The Genetic Basis, Lung Involvement, and Therapeutic Options in Niemann–Pick Disease: A Comprehensive ReviewBiomolecules, 2024
- The Niemann-Pick type diseases – A synopsis of inborn errors in sphingolipid and cholesterol metabolismProgress in Lipid Research, 2023
- Heat shock protein amplification improves cerebellar myelination in the Npc1nih mouse modelEBioMedicine, 2022
- Arimoclomol increases the transcription of lysosomal genes, including and , to facilitate lysosomal functionMolecular Genetics and Metabolism, 2022
- Arimoclomol reduces levels of biomarkers of lipid burden in patients with Niemann-Pick disease type CMolecular Genetics and Metabolism, 2022
- Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatmentJournal of Inherited Metabolic Disease, 2021
- Validation of the 5-domain Niemann-Pick type C Clinical Severity ScaleOrphanet Journal of Rare Diseases, 2021
- Heat shock protein–based therapy as a potential candidate for treating the sphingolipidosesScience Translational Medicine, 2016